Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)

PHASE3UnknownINTERVENTIONAL

Enrollment

260

Participants

Timeline

Start Date

August 13, 2019

Primary Completion Date

October 30, 2021

Study Completion Date

April 30, 2022

Conditions

ALK-positive NSCLC

Interventions

DRUG

TQ-B3139

a multi-target protein kinase inhibitor.

DRUG

Crizotinib

a multi-target protein kinase inhibitor.

Trial Locations (1)

RECRUITING

Sun Yat-Sen University Cancer Center, Guangzhou